Baig Jalal, Shokouh-Amiri Mohammad, Chan Juliana, Chowdhery Rozina, Danthurthy Samaya, Venepalli Neeta K
Department of Medicine, Division of Hematology/Oncology, University of Illinois at Chicago, Chicago, Illinois, USA.
Department of Medicine, Department of Pathology, University of Illinois at Chicago, Chicago, Illinois, USA.
Case Rep Oncol. 2019 Jul 3;12(2):506-512. doi: 10.1159/000500242. eCollection 2019 May-Aug.
Gemcitabine is widely utilized in the treatment of pancreatic, ovarian, and non small cell lung cancers. Gemcitabine is associated with a wide spectrum of lung toxicities, ranging from dyspnea 25% of patients to severe pulmonary toxicity in up to 5% of patients. There is a dearth of information specific to pulmonary toxicity in the setting of gemcitabine combination chemotherapy. Given the potential severity, it is important to identify it early by excluding more common etiologies. We share two case reports of patients with pancreatic cancer who developed severe pulmonary toxicity during gemcitabine combination chemotherapy. Both cases emphasize the heightened risk of pulmonary toxicity in patients receiving gemcitabine chemotherapy combinations, and a need to be vigilant to initiate appropriate therapies immediately.
吉西他滨广泛应用于胰腺癌、卵巢癌和非小细胞肺癌的治疗。吉西他滨与多种肺部毒性相关，从25%的患者出现呼吸困难到高达5%的患者出现严重肺部毒性。在吉西他滨联合化疗的情况下，缺乏关于肺部毒性的具体信息。鉴于其潜在的严重性，通过排除更常见的病因早期识别它很重要。我们分享两例胰腺癌患者在吉西他滨联合化疗期间发生严重肺部毒性的病例报告。这两例病例均强调了接受吉西他滨化疗联合方案的患者发生肺部毒性的风险增加，以及需要警惕并立即启动适当治疗。
